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Abstract
Background: Anti Mullerian hormone (AMH) has previously been measured using a manual method, but a fully
automated assay from Roche Diagnostics was recently introduced. The aim of this study was to compare the results
from the AMH gen II ELISA and Elecsys Cobas AMH methods in a clinical setting to evaluate whether the assays
achieve the goals of analytical performance.
A prospective observational study with 23 women seeking laparoscopic sterilization was conducted. Blood samples
were collected preoperatively as well as 1 week and 1, 3 and 6 months postoperatively; they were evaluated with
the AMH gen II ELISA and Elecsys Cobas AMH methods. The assays were validated according to the optimal
performance of biochemical assays: CVAnalytical < 0.25* CV Within Biological Variation.
Findings: We found a good correlation between the two methods; there was a bias of approximately 32 %.
The total within-person biological variability ranged from approximately 21 to 32 %. The analytical variability
of the AMH gen II ELISA and Elecsys Cobas methods ranged from 5.5 to 10.3 % and 2.8 to 3.3 %, respectively.
Applying the goals for optimal assay performance, the Elecsys Cobas method achieved optimal performance
throughout the measuring range, whereas the AMH Gen II only achieved optimal performance in the high
end of the measuring range. Furthermore, the Elecsys Cobas assay had a low limit of quantitation of 0.5 pmol/l
compared to 3.0 pmol/l for the AMH gen II ELISA.
Conclusions: In the clinical setting, the Elecsys Cobas AMH assay performs well according to the optimal standard
for biochemical assays.
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Introduction
Anti Müllerian Hormone (AMH) is increasingly being
used as a biochemical marker for the assessment of the
growing ovarian pool and thus as a surrogate marker for
the ovarian reserve and female fertility [1]. AMH was
originally introduced as a marker with minimal variation
during the menstrual cycle [2, 3] in opposition with
other markers that have hitherto been used, such as
follicle stimulating hormone (FSH) and inhibin. How-
ever, recent publications have demonstrated intra-cycle
fluctuations, with the highest levels in the early follicular
phase and the lowest levels in the late luteal phase [4],
as well as substantial circadian variations [5]. This
should be interpreted with caution because the results
are based on a small number of samples, and they are
influenced by assay performance. It must be considered
that the total variation associated with the measurement
of AMH is a combination of the within-person variation
and a variation linked to the assay itself, which is
represented as follows: CVTOTAL = √ [(CVWithin-person
Biological Variation)
2 + (CVAnalytical)
2] [6]. In clinical bio-
chemistry, the setting of analytical goals based on the
within-person biological variability is often considered
the most appropriate, and the optimal performance
(CVAnalytical < 0.25 CV Within Biological variation), should be
achieved when the technology and methodology are
available [6].
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Until recently, AMH has been measured with an
enzyme-linked immunosorbent assay (ELISA, Beckmann
Coulter), which is a manual technique characterized by
large analytical variation. However, a new automated
assay (Elecsys Cobas, Roche), which shows good inter-
mediate imprecision, has recently been introduced for
measuring AMH [7].
The aim of this study was to compare the utility of the
two assays in a clinical setting to evaluate whether the
assays meet the goals of analytical performance. We
investigated the blood samples collected from women who
participated in a study examining the potential changes in
ovarian reserve following laparoscopic sterilization as an
example of minimally invasive pelvic surgery.
Material and methods
A prospective observational pilot study with a total of
31 women requesting laparoscopic sterilization were
included. In total, 23 women with a median age of
36 years (range 33–38 years) completed the study.
Patients were included between October 2013 and
May 2014. Patients follow-up was conducted until
October 2014. Blood samples were analyzed in
November/December 2014. The exclusion criteria
were endocrine disease, oligomenorrhea (>30 day cycle),
polycystic ovarian syndrome (PCOS) (Rotterdam criteria),
hormonal contraception, giving birth ≤ 3 months prior to
the inclusion date, postmenopausal status, or suspected
malignancy.
Blood samples were collected to assess the levels of
AMH prior to surgery, one week after surgery and 1,
3 and 6 months after surgery. Serum was isolated
within 4 h of sampling and stored at minus 80 °C
until analysis.
Ultrasound examination to evaluate both the antral
follicle count (AFC) and ovarian volume (OV) was
performed.
Laparoscopic sterilization was performed under gen-
eral anesthesia by a two-port technique. Fallopian tubes
were grasped 2 cm lateral to the uterine corners and
bipolar coagulation was used.
Ultrasound measurements were performed using the
Volusom E6 (6.6 MHz transducer) or the Logiq 9
(8 MHz transducer). The number of follicles that were
between 2–10 mm in diameter in both ovaries were
determined as well as the average ovarian volume
(½*D1*D2*D3).
All biochemical measurements of AMH were per-
formed at the Department of Clinical Biochemistry,
Aarhus University Hospital by skilled technicians. The
laboratory is licensed according to the ISO 15189
accreditation standard for clinical laboratories.
For the Beckmann Coulter AMH Gen II ELISA, the
standard application protocol of employing a pre-
mixture of clinical samples, calibrators and controls in
assay buffer was used. A standard manual technique was
used. The limit of acceptance for daily internal controls
in the two levels was CV < 11–14 %. The limit of
quantitation (LOQ) (lowest concentration of analyte
that can be quantified with a coefficient of variation
(CV %) < 15 %) was 3.0 pmol/l. The measuring range
without dilution was 3–70 pmol/l. Samples were ana-
lyzed in duplicate, and the middle value of two re-
sults was used. If duplicate results differed by more
than 15 %, the analysis was repeated.
The Elecsys Cobas AMH was analyzed on a Cobas
6000 e601 platform using Roche’s standard protocol. The
measuring range without dilution was 0.5–160 pmol/l. The
limit of acceptance for daily internal controls in two levels
was CV < 5 %, and the LOQ was 0.5 pmol/l.
Spearman’s correlation test was used to determine the
correlation between the AMH and total AFC, and the
ovarian volume was calculated using STATA 13 software
(StataCorp, Texas, USA). Passing-Bablok and Bias plots
were made in Analyse-it (Analyse-it Software, Ltd).
The study was approved by the Central Denmark
Region Committees on Health Research Ethics, Journal
number 1–10–72–260–13, 8th of October 2013.
Results
Twenty-three of 31 (74 %) women with a median age
of 36 years (range 33–38 years) completed the study.
The median BMI was 25 (range 22.2–28.7). A total
of 112 serum samples from 23 women were included
in the study. One woman missed the 3- and 6-month
samplings, and one woman missed the 6-month
sampling.
Ovarian reserve
The mean concentrations of AMH measured by Cobas
and ELISA correlated significantly with the total AFC
and were as follows: at baseline, Cobas AMH vs.
AFC: 0.83 (0.6–0.92) (Spearman r (95 % confidence
interval)) and ELISA AMH vs. AFC: 0.86 (0.67–0.94);
at the 3-month follow-up, Cobas AMH vs. AFC: 0.83
(0.60–0.93) and ELISA AMH vs. AFC: 0.81 (0.56–0.92)
(p <0.0001). Significant correlations were also observed
between AMH measured and the ovarian volume by both
Cobas and ELISA (not shown).
AMH, the total AFC, and OV did not change signifi-
cantly during the 6-month follow-up period from the
baseline levels prior to surgery.
Comparison of the two assays
Analyzing controls on consecutive days, we found a
large difference in the analytical variation between the
two methods. As seen in Table 1, the analytical variance
for the Elecsys Cobas method was approximately 3 % in
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the high and low ranges compared with the ELISA
method, which showed a larger variation in the high
range and a particularly larger variation in the low range
with a CV of more than 10 %.
As depicted in Fig. 1, the concentrations of AMH
measured by the Elecsys Cobas assay were, on average,
32 % lower than the concentrations measured by ELISA
(Fig. 1a), and there was a tendency of increased bias be-
tween the two assays in the high concentration range
(Fig. 1b).
The total variance (biological and analytical) in the
clinical samples was divided in two levels, < and > 10
pmol/l. The total variance (mean CV%) in the < 10
pmol/l group was 32 % when measured by ELISA and
28 % when analyzed using the Elecsys Cobas method.
For concentrations > 10 pmol/l, the CV was approxi-
mately 22 % according to both assays. Applying the goals
for analysis (CVAnalytical < 0.25 CV Within-person Biological
Variation), the analytical variation should not exceed 5.3 %
and 7.6 % in the two levels, respectively. This was
achieved by the Elecsys Cobas assay throughout the
measuring range, whereas the AMH Gen II ELISA failed
to meet the goals in the low measuring range.
The limit of quantitation (LOQ) (CV < 15 %) was 3
pmol/l for the ELISA and 0.5 pmol/l for the Elecsys
Cobas method. Accordingly, approximately 15 % of the
measurements were below the LOQ for the ELISA assay,
but only 2 % were below the LOQ for the Elecsys Cobas
method.
Discussion
The main purpose of the present report was to compare
two assays for measuring AMH in a clinical setting.
As expected, there were no changes in the ovarian
reserve parameters (AMH, AFC or OV) during a follow-up period of 6 months. Comparing the AMH
Gen II ELISA and Elecsys Cobas methods, we found
an almost constant bias between the two assays.
Judging from the external quality assessment pro-
gram for AMH (UKNEQAS peptide hormones
(WWW.UKNEQAS.ORG.UK)), the bias between the two
assays is in the range of 5–15 %. Our laboratory has
previously observed a positive bias using the same
program of approximately 20 % when we reported re-
sults for the AMH Gen II ELISA assay. Therefore,
interlaboratory bias may account for the observed
bias, which is somewhat larger than previously pub-
lished [7]. We found a total variation in the repeated
analysis over 6 months ranging between 21 % and
32 % depending on the level of the measurements
and the assay. This means that the within-person bio-
logical variation ranges between 21 % and 30 %. This
variation is similar to data from Rustamov et al., who
reported a 28 % within-person biological variation in
a population of 186 subfertile patients with repeated
Table 1 Performance of Beckmann Coulter AMH Gen II ELISA
and Elecsys Roche AMH assay
ELISA (n = 38) Cobas (n = 40)
Level CV% Level CV%
Control 1 40 pmol/l 5.2 40 pmol/l 3.3
Control 2 20 pmol/l 6.2 - -
Control 3 7 pmol/l 10.3 7 pmol/l 2.8
Total CV% (<10 pmol/l) (n = 11) 31.9 (11.9–47.3) 28.0 (9.5–43.0
Total CV% (>10 pmol/l) (n = 12) 22.0 (11.9–35.2) 21.3 (11.6–33.6)
Percentage of samples without
quantitation
15 % 2 %
Controls were analyzed on consecutive days of analysis over a period of
3 months. Data are given as CV% (Standard deviation x 100/ mean). Results of
variance of clinical samples are given in two levels: < and >10 pmol/l (because
of bias between the two methods, the level differ between the two groups.).
Data are given as CV% (range). Percentage of samples without quantiation is
determined as the percentage of results < 3 pmol/l (ELISA), and < 0.5 pmol/l
(Elecsys Cobas)
Fig. 1 Comparison between the Beckmann Coulter AMH Gen II
ELISA and Elecsys Roche AMH (Anti Müllerian Hormone) assays.
a: Passing-Bablok plot displaying the regression (solid line) and
95 % confidence interval (dotted lines) and b: Bias plot displaying
the difference between methods (as a percentage). Results are
given in pmol/l
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measurements of AMH (median interval of 2.6 months
between samples) [8].
Because the Elecsys Cobas assay can reliably measure
concentrations as low as 0.5 pmol/l, it is now possible to
achieve precise quantitative measurements for a low
level of AMH (<3 pmol/l). This can be beneficial and
useful for clinical evaluation of the ovarian reserve of
women before undergoing assisted reproductive technol-
ogy or in the case of imminent menopause.
Conclusion
There was a good correlation between the Elecsys Cobas
AMH and AMH Gen II ELISA methods for the entire
measuring range. While the goals for optimal analytical
performance were achieved with the Elecsys Cobas
assay, they were not met with the AMH Gen II ELISA
assay. This is important in the clinical setting because
women seeking treatment for infertility often have a low
AMH; therefore, analysis with Elecsys Cobas will provide
a better option for assessing AMH in this group of
women in addition to its ability to measure levels as low
as 0.5 pmol/l.
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